Dhanbad News Paper

One-stop CAR-T Discovery Platform at Creative Biolabs to Facilitate Immunotherapy Research

 Breaking News
  • No posts were found

One-stop CAR-T Discovery Platform at Creative Biolabs to Facilitate Immunotherapy Research

December 30
13:10 2020
With an unrelenting drive in the biotechnology research area, Creative Biolabs have accumulated more than 10 years’ experience in exploring and developing innovative therapeutic antibodies, and now releases the updated integrated CAR-T discovery services.

New York, USA – December 30, 2020 – Since the U.S. Food and Drug Administration (FDA) approved two CAR-T therapies targeting CD19 antigen in 2017 for the treatment of B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), CAR-T cell therapy, using genetic engineering to transform patients’ own T cells, and turn them into missiles against cancer, has become one of the hottest topics in cancer treatments.

With more than a decade of exploration and expansion, Creative Biolabs has optimized its one-stop CAR-T discovery services, including a variety of modules of cellular and gene therapy discovery services, covering T cell receptor T cell therapy, chimeric antigen receptor (CAR) T cell therapy, CAR NK cell therapy, CAR macrophage cell therapy, TCR identification, scGV generation and optimization, etc.

• Chimeric Antigen Receptor (CAR) T Cell Therapy

CAR-T therapy has shown its great potential in killing tumor cells for a long time. To accelerate the development of CAR-T based approaches, Creative Biolabs offers an end-to-end solution covering all steps prior to clinical trials for global clients.

The complete portfolio of CAR-T therapy development services includes but is not limited to neoantigen identification, scFV generation, CAR design and construction, CAR-T preparation, in vitro validation and in vivo testing.

• T Cell Receptor(TCR) T Cell Therapy

In clinical trials, TCR-T cell therapies have also produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. Supported by state-of-the-art technical platforms, expert teams at Creative Biolabs is confident to offer flexible solutions related to TCR-T cell therapy.

To develop TCR-T based approaches, Creative Biolabs offers streamlined end-to-end TCR-T services covering tumor-specific TCR identification, tumor-specific TCR generation and optimization, TCR design and construction, TCR-T preparation, in vitro validation and in vivo testing. Scientists at Creative Biolabs promise easier project management and less time to market.

Creative Biolabs is dedicated to custom services and products related to a full spectrum of targets in the immune system, such as T cell, B cell, NK cell, DC and macrophage. Besides, various bioassays, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) testing, immunoassay, FcR binding assay, immune cells function assay, immuno-oncology assay, etc.

More information can be found on https://www.creative-biolabs.com/immuno-oncology.

About Creative Biolabs

With a great passion for the new chapter of cancer treatment, Creative Biolabs believes that next-generation immunotherapy will provide the best opportunity to discover and advance the drug pipeline for global partners. The expert team now introduces the first-class therapeutic antibody and protein platforms to guide clients through challenges from target selection to IND regulatory support.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/immuno-oncology